HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection

被引：118
|
作者：
Kemp, Troy J. [1 ]
Hildesheim, Allan [2 ]
Safaeian, Mahboobeh [2 ]
Dauner, Joseph G. [1 ]
Pan, Yuanji [1 ]
Porras, Carolina [3 ]
Schiller, John T. [4 ]
Lowy, Douglas R. [4 ]
Herrero, Rolando [3 ]
Pinto, Ligia A. [1 ]
机构：
[1] NCI Frederick, HPV Immunol Lab, SAIC Frederick Inc, Frederick, MD 21702 USA
[2] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA
[3] Fdn INCIENSA, Proyecto Epidemiol Guanacaste, San Jose, Costa Rica
[4] NCI, Cellular Oncol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
来源：
VACCINE | 2011年 / 29卷 / 11期
基金：
美国国家卫生研究院;
关键词：
Human papillomavirus; Antibody; Vaccine; PARTICLE VACCINE; YOUNG-WOMEN; INFECTION; EFFICACY; IMMUNIZATION; RESPONSES; TYPE-18; HPV-18;
D O I：
10.1016/j.vaccine.2011.01.001
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Human papillomavirus (HPV) L1 VLP-based vaccines are protective against HPV vaccine-related types; however, the correlates of protection have not been defined. We observed that vaccination with Cervarix (TM) induced cross-neutralizing antibodies for HPV types for which evidence of vaccine efficacy has been demonstrated (HPV31/45) but not for other types (HPV52/58). In addition, HPV31/45 cross-neutralizing titers showed a significant increase with number of doses (HPV31, p < 0.001; HPV45, p < 0.001) and correlated with HPV16/18 neutralizing titers, respectively. These findings raise the possibility that cross-neutralizing antibodies are effectors of cross-protection observed for the HPV16/18 vaccine.(C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码：2011 / 2014
页数：4
相关论文
共 48 条
  • [31] Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine
    Olsson, Sven-Eric
    Villa, Luisa L.
    Costa, Ronaldo L. R.
    Petta, Carlos A.
    Andrade, Rosires P.
    Malm, Christian
    Iversen, Ole-Erik
    Hoye, John
    Steinwall, Margareta
    Riis-Johannessen, Grete
    Andersson-Ellstrom, Agneta
    Elfgren, Kristina
    von Krogh, Geo
    Lehtinen, Matti
    Paavonen, Jorma
    Tamms, Gretchen M.
    Giacoletti, Katherine
    Lupinacci, Lisa
    Esser, Mark T.
    Vuocolo, Scott C.
    Saah, Alfred J.
    Barr, Eliav
    VACCINE, 2007, 25 (26) : 4931 - 4939
  • [32] Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix™, the AS04-adjuvanted HPV-16 and-18 cervical cancer vaccine
    Deschuyteneer, Michel
    Elouahabi, Abdelatif
    Plainchamp, Dominique
    Plisnier, Michel
    Soete, Dominique
    Corazza, Yvon
    Lockman, Laurence
    Giannini, Sandra
    Deschamps, Marguerite
    HUMAN VACCINES, 2010, 6 (05): : 407 - 419
  • [33] Whole recombinant Pichia pastoris expressing HPV16 L1 antigen is superior in inducing protection against tumor growth as compared to killed transgenic Leishmania
    Bolhassani, Azam
    Muller, Martin
    Roohvand, Farzin
    Motevalli, Fatemeh
    Agi, Elnaz
    Shokri, Mehdi
    Rad, Mahdieh Motamedi
    Hosseinzadeh, Sahar
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (12) : 3499 - 3508
  • [34] How has post-implementation surveillance of high-coverage vaccination with HPV16/18-AS04 vaccine in England added to evidence about its cross-protective effects?
    Navarro-Torne, Adoracion
    Anderson, Anja
    Ghys, Emmanuelle
    Benninghoff, Bernd
    Weynants, Vincent
    Beddows, Simon
    Checchi, Marta
    VACCINE, 2024, 42 (24)
  • [35] ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants
    Seow, Jeffrey
    Graham, Carl
    Hallett, Sadie R.
    Lechmere, Thomas
    Maguire, Thomas J. A.
    Huettner, Isabella
    Cox, Daniel
    Khan, Hataf
    Pickering, Suzanne
    Roberts, Rebekah
    Waters, Anele
    Ward, Christopher C.
    Mant, Christine
    Pitcher, Michael J.
    Spencer, Jo
    Fox, Julie
    Malim, Michael H.
    Doores, Katie J.
    CELL REPORTS, 2022, 39 (05):
  • [36] Prevalence of oncogenic Human papillomavirus and genetic diversity in the L1 gene of HPV16 HPV 18 HPV31 and HPV33 found in women from Vojvodina Province Serbia
    Kovacevic, Gordana
    Milosevic, Vesna
    Knezevic, Petar
    Knezevic, Aleksandra
    Knezevic, Ivana
    Radovanov, Jelena
    Nikolic, Natasa
    Patic, Aleksandra
    Petrovic, Vladimir
    Cvjetkovic, Ivana Hrnjakovic
    Stanisic, Ljiljana
    BIOLOGICALS, 2019, 58 : 57 - 63
  • [37] A live attenuated glycoprotein E negative bovine herpesvirus 1 vaccine induces a partial cross-protection against caprine herpesvirus 1 infection in goats
    Thiry, J
    Tempesta, M
    Camero, M
    Tarsitano, E
    Bellacicco, AL
    Thiry, E
    Buonavoglia, C
    VETERINARY MICROBIOLOGY, 2006, 113 (3-4) : 303 - 308
  • [38] One-prime multi-boost strategy immunization with recombinant DNA, adenovirus, and MVA vector vaccines expressing HPV16 L1 induces potent, sustained, and specific immune response in mice
    Li, Li-Li
    Wang, He-Rong
    Zhou, Zhi-Yi
    Luo, Jing
    Xiao, Xiang-Qian
    Wang, Xiao-Li
    Li, Jin-Tao
    Zhou, Yu-Bai
    Zeng, Yi
    ANTIVIRAL RESEARCH, 2016, 128 : 20 - 27
  • [39] The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years
    Brown, Darron R.
    Kjaer, Susanne K.
    Sigurdsson, Kristjan
    Iversen, Ole-Erik
    Hernandez-Avila, Mauricio
    Wheeler, Cosette M.
    Perez, Gonzalo
    Koutsky, Laura A.
    Tay, Eng Hseon
    Garcia, Patricia
    Ault, Kevin A.
    Garland, Suzanne M.
    Leodolter, Sepp
    Olsson, Sven-Eric
    Tang, Grace W. K.
    Ferris, Daron G.
    Paavonen, Jorma
    Steben, Marc
    Bosch, F. Xavier
    Dillner, Joakim
    Joura, Elmar A.
    Kurman, Robert J.
    Majewski, Slawomir
    Munoz, Nubia
    Myers, Evan R.
    Villa, Luisa L.
    Taddeo, Frank J.
    Roberts, Christine
    Tadesse, Amha
    Bryan, Janine
    Lupinacci, Lisa C.
    Giacoletti, Katherine E. D.
    Sings, Heather L.
    James, Margaret
    Hesley, Teresa M.
    Barra, Eliav
    JOURNAL OF INFECTIOUS DISEASES, 2009, 199 (07): : 926 - 935
  • [40] Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines
    Wheeler, Cosette M.
    Bautista, Oliver M.
    Tomassini, Joanne E.
    Nelson, Margaret
    Sattler, Carlos A.
    Barr, Eliav
    VACCINE, 2008, 26 (05) : 686 - 696
12345